Cradle, a protein engineering artificial intelligence startup based in the Netherlands and Switzerland, recently announced the successful completion of a $73 million Series B funding round. This round was led by investment firm IVP, with participation from existing investors Index Ventures and Kindred Capital. With this funding, Cradle's total financing has now exceeded $100 million.
Image Source Note: Image generated by AI, image licensed from Midjourney
Cradle is dedicated to accelerating the research process in protein engineering through its artificial intelligence platform. The company states that this platform simplifies the protein development process, reduces costs, and minimizes the time and resources researchers need to develop and improve proteins. This efficient technological approach enables researchers to achieve the desired results more quickly, driving advancements in biotechnology.
With this funding secured, Cradle plans to expand its wet lab facilities and further enhance its machine learning systems. The company has already established partnerships with several well-known biotechnology firms, including Novo Nordisk and Ginkgo Bioworks. These collaborations not only provide Cradle with technical advancements but also offer broad prospects for the practical application of its products.
Protein engineering is a crucial area of research in life sciences, with widespread applications in pharmaceuticals, agriculture, and various other industries. Cradle's innovative solutions aim to meet the growing demands in this field. Through intelligent means, Cradle hopes to make protein development more efficient, thereby promoting advancements in biotechnology and facilitating the development of new drugs.
The founding team of Cradle expressed their confidence in future developments and look forward to collaborating with more partners to drive innovation in the biotechnology industry. With the funding in place, the company will accelerate its efforts to commercialize its technology, assisting global researchers in achieving greater breakthroughs in protein engineering.
Key Points:
💰 Cradle successfully completed a $73 million Series B funding round, with total funding exceeding $100 million.
🔬 The company's AI platform aims to accelerate protein engineering development, simplifying processes and reducing costs.
🤝 Cradle has established partnerships with several biotechnology companies, including Novo Nordisk and Ginkgo Bioworks.
